Menu Search
Equities

China Biotech Services Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8037:HKG.HZ

China Biotech Services Holdings Ltd

Actions
  • Price (HKD)0.70
  • Today's Change-0.01 / -1.41%
  • Shares traded420.00k
  • 1 Year change+86.67%
  • Beta0.1263
Data delayed at least 15 minutes, as of Jul 03 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.

  • Revenue in HKD (TTM)70.51m
  • Net income in HKD-198.15m
  • Incorporated2013
  • Employees141.00
  • Location
    China Biotech Services Holdings LtdRoom 1213, Tower A, New Mandarin Plaza14 Science Museum RoadKowloon Hong KongHKG
  • Phone+852 31883333
  • Fax+852 21513968
  • Websitehttp://www.cbshhk.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.